ASLAN Pharmaceuticals Limited (ASLN)

Market Cap	7.88M
Revenue (ttm)	12.00M
Net Income (ttm)	-44.22M
Shares Out	17.60M
EPS (ttm)	-2.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	314,626
Open	0.470
Previous Close	0.470
Day's Range	0.441 - 0.489
52-Week Range	0.392 - 4.690
Beta	1.47
Analysts	Strong Buy
Price Target	11.33 (+2,429.02%)
Earnings Date	Apr 12, 2024

About ASLN

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 4, 2018
• Employees: 35
• Stock Exchange: NASDAQ
• Ticker Symbol: ASLN

Analyst Forecast

According to 3 analysts, the average rating for ASLN stock is "Strong Buy." The 12-month stock price forecast is $11.33, which is an increase of 2,429.02% from the latest price.

Price Target

$11.33

(2,429.02% upside)

Analyst Consensus: Strong Buy